RNAi-based method of drug screening and characterization

Patent metadata

Field	Value
Publication number	US-9683231-B2
Application number	US-201113993930-A
Country	US
Kind code	B2
Filing date	Dec 16, 2011
Priority date	Dec 16, 2010
Publication date	Jun 20, 2017
Grant date	Jun 20, 2017

Abstract

The invention is directed to a method of characterizing a mechanism of action of an agent (e.g., a chemotherapeutic agent, a genotoxic agent). The method comprises contacting a plurality of populations of cells with an agent to be assessed, wherein each population of cells have one gene of interest targeted by a small hairpin RNA (shRNA) and wherein said gene of interest regulates cell death and a plurality of genes that regulate cell death are targeted in the plurality of populations of cells. A responsiveness of each population of cells to the agent is determined, thereby obtaining an shRNA signature of the agent, so as to identify one or more genes that mediate a response to the agent, thereby characterizing the mechanism of action of the agent. The invention is also directed an article of manufacture for characterizing a mechanism of action of a chemotherapeutic or genotoxic agent.

First claim

What is claimed is:

1. A method of characterizing a mechanism of action of an agent comprising:
a) contacting each of eight populations of cells with an agent to be assessed, wherein each population of cells expresses a small hairpin RNA (shRNA) that targets one of eight genes present in the cells, said eight genes consisting of p53, ATR, Chk1, Chk2, Smg-1, DNA-PKcs, Bok, and Bim genes; and
b) determining a responsiveness of each of the eight populations of cells to the agent to obtain a combined shRNA signature of the agent for the eight populations of cells,

thereby characterizing the mechanism of action of the agent.

2. The method of claim 1 wherein the mechanism of action of the agent comprises inhibition of a topoisomerase, cross linking of DNA, inducement of single stand break of DNA, inhibition of nucleic acid synthesis, inhibition of mitosis, inhibition of RNA transcription, inhibition of histone modification enzymes, inhibition of heat shock proteins, alkylation of DNA, or inhibition of proteasomes inducement of apoptosis.

3. The method of claim 1 further comprising classifying the agent within a group of agents having in common one or more mechanisms of action.

4. The method of claim 1 wherein each shRNA acts to knock down the gene that it targets.

5. The method of claim 1 wherein the agent is used in an effective amount to induce a response in cells that do not contain shRNA targeting any of said eight genes.

6. The method of claim 1 wherein the agent is a derivative of a chemotherapeutic agent.

7. The method of claim 1 wherein the responsiveness of each of the populations of cells to the agent is a relative level of chemo-resistance and sensitization conferred by each shRNA.

8. The method of claim 1 wherein the responsiveness of each of the populations of cells to the agent is a relative survival rate compared to control cells that do not contain shRNA targeting any of the eight genes.

9. The method of claim 1 wherein each of the populations of cells further expresses a marker gene.

10. The method of claim 1 wherein the shRNAs are introduced into the cells using a viral vector.

11. The method of claim 10 wherein the viral vector is a retroviral vector.

12. The method of claim 10 wherein the vector further expresses a marker gene.

13. The method of claim 9 wherein the marker gene is a fluorescent marker gene.

14. The method of claim 9 wherein the marker gene is green fluorescent protein (GFP) gene.

15. The method of claim 13 further comprising measuring the fluorescent marker gene or GFP gene expression level in each of the populations of cells using flow cytometry.

16. The method of claim 1 further comprising comparing the responsiveness of each of the populations of cells to the agent to a control.

17. The method of claim 16 wherein the control is a population of cells into which no shRNA targeting any of the eight genes has been introduced.

18. The method of claim 1 wherein the determination of the responsiveness is accomplished using cell flow cytometry, hybridization techniques or sequencing techniques.

19. The method of claim 1 wherein each of the populations of cells is contacted repeatedly with the agent.

20. The method of claim 1 further comprising introducing the shRNAs into each of the populations of cells.

21. The method of claim 1 further comprising, using a processor, clustering representations of a plurality of agents into groups based on the responsiveness of each of the populations of cells to each agent.

22. The method of claim 1 wherein the agent is a chemotherapeutic or genotoxic agent.

23. The method of claim 1 wherein the agent is a chemical compound.

24. The method of claim 1 further comprising assessing whether the agent has a chemotherapeutic or genotoxic effect.

25. The method of claim 21 wherein clustering the representations of the plurality of agents into groups includes:
determining an initial cluster size of a group of agents by determining an average of pairwise linkage distances among the group of agents, the group of agents formed based on the responsiveness of each of the populations of cells to each agent of the group;
predicting whether the agent belongs to the group using a k-nearest neighbor calculation between the agent and the group of agents; and
if the agent is predicted to belong to the group, adding the agent to the group and determining a new cluster size for the group of agents, and determining a linkage ratio for the agent and the group of agents based on the initial cluster size and the new cluster size.

26. The method of claim 25 wherein a linkage ratio of less than one indicates that adding the agent to the group reduced an average distance between agents in the group, and a linkage ratio of greater than one indicates that adding the agent to the group increased an average distance between agents in the group.

27. The method of claim 25 wherein the k-nearest neighbor calculation includes cross-validating the group of agents by leaving out one of the agents from the group and predicting the left-out agent's identity based on the remaining agents in the group.

28. The method of claim 25 further comprising estimating a significance of adding the agent to the group by sampling negative control distributions of the group of agents.

29. The method of claim 25 further comprising determining distances between a plurality of groups using a centroid linkage.

30. The method of claim 29 further comprising estimating a significance of the groupings using a Monte Carlo analysis.

Assignees

• Jiang Hai
• Pritchard Justin
• Lauffenburger Douglas A
• Hemann Michael
• Massachusetts Inst Technology

Inventors

• Jiang Hai
• Pritchard Justin
• Lauffenburger Douglas A
• Hemann Michael

Classifications

• C12Q1/6886

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/136

  Screening for pharmacological compounds · CPC title

• G01N33/5023

  on expression patterns · CPC title

• C12Q2600/178

  miRNA, siRNA or ncRNA · CPC title

• C12Q1/6883

  for diseases caused by alterations of genetic material · CPC title